FierceBiotech17m
Merck sets sights on brain cancer with $30M Modifi acquisition
Merck & Co. is putting down $30 million cash to buy Yale spinout Modifi Biosciences, a deal that includes a preclinical asset ...
Modifi Biosciences Acquired by Merck
Merck gains preclinical compounds designed to exploit DNA repair defects in difficult to treat cancersNEW HAVEN, Conn., Oct.
FierceBiotech2d
Merck-Gilead long-acting oral combo suppresses HIV for 48 weeks, setting stage for pivotal program
Gilead and Merck & Co. have guided their once-weekly HIV combination therapy past another milestone, linking the cocktail to ...
Pharmabiz8d
Exelixis, Merck enter clinical development collaboration to evaluate zanzalintinib in combo with Keytruda in HNSCC and in combo with Welireg in RCC
Alameda, California Tuesday, October 15, 2024, 14:00 Hrs [IST] ...
Exelixis, Merck Sign Clinical Development Deal To Evaluate Zanzalintinib With KEYTRUDA, WELIREG
Drug makers Exelixis, Inc. (EXEL) and Merck & Co Inc.(MRK) announced Monday that they have entered into a clinical development ...
Business Wire3d
Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapav…
Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...
Yahoo Finance22d
Merck Completes Acquisition of Investigational B-Cell Depletion Therapy, CN201, from Curon Biopharmaceutical
Addition of CN201, a next generation CD3xCD19 bispecific antibody with potential applications in B-cell malignancies and autoimmune diseases, broadens and fortifies Merck’s pipeline RAHWAY ...
pharmaphorum1d
Merck gets FDA okay for Keytruda as liver cancer therapy
Merck & Co/MSD has won approval in ... as an adjuvant treatment for ALK-positive non-small cell lung cancer (NSCLC), the first targeted therapy for this indication.
Merck Welcomes Funded Access To Cancer Treatment Erbitux® (Cetuximab)
Globally recognised as a first-line standard of care, the public funding of ERBITUX® (cetuximab) [1] marks an important development for people living with left-sided RAS wild-type and BRAF wild-type ...